Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A for calf spasticity in hereditary spastic paraplegia
NL-OMON32926Phase 4Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in hereditary spastic paraplegia (HSP), sponsored by Radboud University Medical Center. Primary endpoint: Dynamic balance. Started Sep 2009; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
hereditary spastic paraplegia (HSP)
Beyond the preview
Go deeper on NL-OMON32926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32926.